QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Ironwood Pharmaceuticals, Inc. (IRWD)

Healthcare

Actionable
Fundamental
3
Sentiment
3
Technical
4

Buy pullback: limit 4.74 (GTC) at the lower shelf of the 4.74-5.00 flag (2026-11-11 swing low, retest of the 2026-11-09 breakout-day high 4.76), protective stop 4.51 (the 1.0xATR pullback floor beneath the 4.65 structural low), targets 5.20 and 5.55, R/R 2.00; a buy-stop breakout above the settled 5.00 flag high (trigger 5.01, stop 4.71, R/R 1.53) was also evaluated and passed the floors, but the better-priced dip entry is preferred into an overbought tape (RSI14 74.91).

Analysis as of 2026-11-15· more than 2 trading days ago

Company overview

Ironwood Pharmaceuticals, Inc. focuses on developing and commercializing treatments for gastrointestinal conditions. Its main product, linaclotide, is marketed as LINZESS in the U.S. and Mexico, and as CONSTELLA in Canada and the EU. The company also has a pipeline including IW-3300 for visceral pain and CNP-104 for biliary cholangitis. Ironwood collaborates with AbbVie, AstraZeneca, and Astellas Pharma.

Fundamental

fair
Fundamental3
Mixed fundamentals

Ironwood's strong cash flow and deleveraging are offset by revenue dependency on a single product and negative book equity.

Mixed but cash-rich: trailing-twelve-month free cash flow of roughly $205M against an $800M market capitalization, net leverage under 1x after repaying $260M of debt in nine months, covenants in compliance, no going-concern language and guidance raised twice for 2026. Set against that, all revenue derives from AbbVie and roughly 98% from a single molecule whose settled generic entry date is as early as March 2029 and whose Medicare negotiated price begins January 2027. Negative book equity, rebate-estimate-driven revenue volatility and a one-sided pattern of insider sales keep the overall profile mixed rather than solid.

Sentiment

fair
Sentiment3
Mixed / forming

Recent positive media sentiment is countered by insider selling and a lack of upcoming catalysts.

Dominant catalyst is the announced 2026-11-05 third-quarter print — record LINZESS U.S. net sales with FY2026 revenue guidance raised to $485–510M and adjusted EBITDA guided above $350M — and the 14-day media polarity is measured bullish at +0.45, with the delta against an under-enriched baseline (+0.10 on a single scored item) reading as improving at item level and moderate confidence. The catalyst is ten days old and largely digested after a roughly 35% re-rating, the consensus price target ($4.80) now sits at spot with no scheduled event inside thirty days, and one moderate flag fired for conflicting catalyst signals (tape-rewarded beat against reported ~$1.3M insider selling) — moderate red-flag cap applied; no severe flag present.

Technical

good
Technical4
Bullish continuation

The stock is in a bullish trend with strong momentum indicators, suggesting potential upside from current levels.

Bullish continuation structure with one clear caution. Trend: price 4.83 sits above the SMA20 (3.93), SMA50 (3.97) and SMA200 (3.95), above EMA9 (4.49), EMA21 (4.15), WMA9 (4.65), WMA21 (4.16) and DEMA14 (4.68), and essentially at the daily VWAP (4.8325). Momentum: MACD 0.27/0.11/0.16 is positive with an expanding histogram, and ADX14 29.50 (up from 15.1 two weeks ago) is read directionally with price above every key MA - a strong UP trend, not a countertrend reading. Volume: $10.03M average 20-day dollar volume and roughly $12.9M over the last three sessions, with consolidation volume contracting from 5.33M to 2.81M shares. Structure: a 3.46 (2026-11-02) to 4.87 (2026-11-11) seven-session post-earnings advance has coiled for three sessions in a 4.74-5.00 flag, leaving the 4.74/4.76 shelf (2026-11-11 swing low, retest of the 2026-11-09 breakout-day high) as the pullback support to bid. The one weak signal is short-term extension - RSI14 74.91, Williams %R -10.62, price roughly 23% above its SMA20 after a 39% nine-session run - which is exactly why the entry is a limit into support at 4.74 rather than a chase. A buy-stop above the settled 5.00 flag high was also built (trigger 5.01, structural stop 4.71, R/R 1.53); it clears the floors but is inferior at this level of extension.

You’re looking at 2026-11-15 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.